News Daily News Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Caitlin E. Cox October 22, 2025
News Daily News Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity L.A. McKeown December 23, 2024
News Daily News FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades Todd Neale October 02, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2023 Caitlin E. Cox December 28, 2023
News Daily News FDA Grants Tirzepatide a New Indication for Obesity Management L.A. McKeown November 08, 2023
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2019 Caitlin E. Cox January 31, 2019
News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017
News Daily News Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina Michael O'Riordan June 30, 2016
News Daily News FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin Michael O'Riordan June 30, 2016